Episodes

  • Decentralized Diagnostics: Regulatory Pathways for AI-Powered Imaging in 2026

    Decentralized Diagnostics: Regulatory Pathways for AI-Powered Imaging in 2026
    Mar 29 2026
    This episode explores the transformative potential of AI-enabled imaging and ultrasound tools designed for non-experts, set to reshape diagnostics by 2026. We dissect the four emerging business models—hardware, workflow software (SaMD), remote interpretation, and population-scale screening—and analyze the unique global regulatory, data privacy, and market access challenges associated with each. Discover which strategies are best positioned to succeed in this new era of decentralized healthcare. Key Questions: - How will AI empower non-specialists to use advanced ultrasound and imaging tools by 2026? - What are the four primary business models emerging from this technology shift? - What specific regulatory hurdles exist for AI-enabled hardware versus Software as a Medical Device (SaMD)? - How do data privacy laws like GDPR and HIPAA impact remote interpretation services? - What are the unique market access challenges for population-scale screening programs? - Why is a unified global regulatory strategy essential for success in this new market? - Which business model is best positioned to capture value by navigating these complexities? Navigating the complex regulatory landscape for AI-driven medical devices is critical. Pure Global specializes in helping innovative MedTech and IVD companies commercialize their products globally. We develop efficient regulatory strategies for complex technologies like Software as a Medical Device (SaMD) and AI-enabled hardware, helping you overcome market access hurdles in over 30 countries. Our integrated approach combines local expertise with advanced AI tools to streamline technical dossier submission and ensure ongoing compliance. To accelerate your global expansion, contact Pure Global at info@pureglobal.com, visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.
    Show more Show less
    4 mins
  • The 2026 Surgical Robotics Shake-Up: FDA Approvals, Specialization, and New Competition

    The 2026 Surgical Robotics Shake-Up: FDA Approvals, Specialization, and New Competition
    Mar 28 2026
    This episode explores the transformative shift in the surgical robotics market, predicting a move away from a single-player monopoly by 2026. We analyze the impact of new FDA-approved platforms from giants like Medtronic and Johnson & Johnson, the rise of specialization in fields such as orthopedics and cardiac surgery, and how competition is now being driven by factors like price, workflow efficiency in ambulatory surgical centers, and the integration of artificial intelligence. - Will the surgical robotics market remain dominated by one giant in 2026? - How are new FDA approvals for Medtronic’s Hugo and J&J’s Ottava changing the competitive landscape? - Is specialization in spine, cardiac, and microsurgery the new frontier for robotic platforms? - How do smaller, modular robots create new opportunities in ambulatory surgical centers (ASCs)? - What role does Artificial Intelligence (AI) play in differentiating the next generation of surgical robots? - Are high costs and complex training no longer significant barriers to robotic surgery adoption? - What does increased competition mean for innovation, hospital procurement, and patient care? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. From developing regulatory strategy and compiling technical dossiers to acting as your in-country representative in over 30 markets, we accelerate your path to commercialization. Our AI and data tools offer powerful market research capabilities, helping you identify the best regions for expansion. Whether you are a startup or a multinational, Pure Global provides efficient, technology-driven solutions for your global ambitions. Contact us at info@pureglobal.com, visit https://pureglobal.com/, or explore our FREE AI tools at https://pureglobal.ai/.
    Show more Show less
    3 mins
  • FDA's New Cybersecurity Era: Why SBOMs and Secure Architecture are Non-Negotiable for MedTech by 2026

    FDA's New Cybersecurity Era: Why SBOMs and Secure Architecture are Non-Negotiable for MedTech by 2026
    Mar 27 2026
    This episode examines how U.S. FDA regulations have repositioned cybersecurity as a core feature of medical devices. We discuss the impact of the Consolidated Appropriations Act of 2023 and the FDA's "Refuse to Accept" policy, exploring why a secure architecture, a Software Bill of Materials (SBOM), and robust incident response plans are now critical for regulatory approval, hospital trust, and commercial success heading into 2026. - What new authority did the FDA gain over medical device cybersecurity in 2023? - Why is a Software Bill of Materials (SBOM) now a mandatory part of FDA submissions? - How has "secure by design" shifted from a best practice to a regulatory necessity? - What are the essential components of a compliant post-market cybersecurity plan? - How will a device's security posture directly influence hospital purchasing decisions by 2026? - What is the FDA's "Refuse to Accept" policy for cybersecurity? - How can manufacturers prepare their technical dossiers for these new requirements? Pure Global offers end-to-end consulting for MedTech and IVD companies, helping you navigate complex regulatory landscapes like the FDA's new cybersecurity rules. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers that meet these stringent new standards. We act as your local representative to ensure continuous compliance and monitor regulatory changes that could impact your market access. Let us help you get to market faster. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.
    Show more Show less
    3 mins
  • FDA's 2026 TEMPO Pilot: The Bridge to Reimbursement for Digital Health?

    FDA's 2026 TEMPO Pilot: The Bridge to Reimbursement for Digital Health?
    Mar 26 2026
    This episode delves into the U.S. FDA's upcoming Total Product Life Cycle (TPLC) Advisory Program, known as TEMPO, set to launch in 2026. We explore its potential to revolutionize the pathway for digital health and chronic-care medical devices by integrating payers early in the regulatory process. We analyze whether TEMPO can successfully bridge the gap between regulatory approval and reimbursement, or if manufacturers will still face significant hurdles in proving value to secure market access. - What is the FDA's TEMPO pilot program launching in 2026? - How does TEMPO aim to connect regulatory approval with payer reimbursement? - Why do many approved digital health devices struggle to get paid for by insurers? - What specific challenges does the program target for chronic-care device makers? - Could TEMPO reduce the time and cost of bringing new MedTech to market? - What are the potential limitations or reasons for skepticism about the pilot's success? - How can manufacturers prepare their evidence strategy for both the FDA and payers? Navigating the complex path from regulatory approval to reimbursement requires a robust strategy. Pure Global offers end-to-end consulting for MedTech and IVD companies, developing efficient pathways for approval that consider payer requirements from the start. We use advanced AI to compile and manage technical dossiers and provide continuous regulatory monitoring to keep you ahead of changes like the TEMPO pilot. Whether you're a startup or a multinational, we help you identify the best markets and build the evidence needed for successful global access. Contact Pure Global at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
    Show more Show less
    3 mins
  • U.S. FDA vs. Wearables: The 2026 Regulatory Showdown for Digital Health

    U.S. FDA vs. Wearables: The 2026 Regulatory Showdown for Digital Health
    Mar 25 2026
    This episode explores the evolving regulatory landscape for digital health, focusing on the U.S. FDA's projected stance in 2026. We dissect the critical line between general wellness wearables and regulated medical devices, analyzing how advanced features like blood pressure monitoring, sleep analysis, and AI coaching are forcing new regulatory clarity. We delve into the importance of a product's intended use, its marketing claims, and the level of risk it presents to the user as key factors in the FDA's classification process. - Where does the FDA draw the line between a wellness wearable and a medical device in 2026? - How do the January 2026 FDA guidance documents redefine "general wellness" for low-risk devices? - Can a wearable that monitors blood pressure be sold without FDA clearance? - What separates an AI-powered wellness coach from regulated Clinical Decision Support software? - Which product claims will automatically classify a digital health app as a medical device? - How does a company's marketing language impact its regulatory obligations? - What are the winning strategies for companies in the wearable technology space? Pure Global offers comprehensive regulatory consulting for MedTech and IVD firms, simplifying global market access. We leverage local expertise across 30+ markets and advanced AI tools to develop efficient regulatory strategies, manage technical dossiers, and ensure post-market compliance. Whether you are a startup or a multinational, our end-to-end solutions help you navigate complex landscapes, from initial market research to gaining and maintaining registration for your devices. Let us be your partner in accelerating your global expansion. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
    Show more Show less
    4 mins
  • FDA's 2026 AI Device Scrutiny: Lifecycle Governance and Real-World Performance

    FDA's 2026 AI Device Scrutiny: Lifecycle Governance and Real-World Performance
    Mar 24 2026
    This episode explores the FDA's expected regulatory landscape for AI-enabled medical devices in 2026. We discuss the critical shift from pre-market assessment to a total product lifecycle approach, focusing on the non-negotiable requirements for real-world performance monitoring and Predetermined Change Control Plans (PCCPs). Learn what will separate scalable, approvable medtech platforms from demo-grade algorithms that cannot withstand long-term regulatory scrutiny. - How will the FDA's definition of 'safe and effective' for AI devices change by 2026? - What is a Predetermined Change Control Plan (PCCP) and why will it be mandatory? - Why is real-world performance monitoring becoming more critical than initial pilot data? - What is 'algorithmic drift' and how must manufacturers plan to manage it? - How does clinical workflow integration impact the regulatory viability of an AI device? - What separates a sustainable medtech platform from a simple AI algorithm? - How can you build a lifecycle governance strategy that meets future FDA expectations? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. From developing a regulatory strategy and compiling your technical dossier to acting as your local representative in over 30 markets, we cover the entire product lifecycle. Our technology-driven approach ensures efficiency and accuracy, helping you navigate complex requirements for market approval and post-market surveillance. To access new markets faster and ensure ongoing compliance, contact Pure Global at info@pureglobal.com, visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.
    Show more Show less
    3 mins
  • Home-Use Device Recalls & Firmware Updates: Navigating the MedTech Logistical Nightmare

    Home-Use Device Recalls & Firmware Updates: Navigating the MedTech Logistical Nightmare
    Mar 15 2026
    This episode delves into the top health technology hazard: the logistical challenges of communicating recalls and firmware updates for home-use medical devices. We explore the fragmented communication chain from manufacturer to patient, the difficulties in executing physical returns and software corrections for non-clinical users, and the regulatory definition of a firmware update as a recall. - Why are home-use device recalls considered the #1 medical tech hazard? - What makes communicating with patients so different from communicating with hospitals? - How does the fragmented supply chain prevent manufacturers from reaching end-users? - Are critical firmware or software updates considered a medical device recall by the FDA? - What were the key communication failures in the massive 2021 CPAP machine recall? - What are the logistical challenges of physically retrieving thousands of devices from patients' homes? - How can companies ensure non-technical users apply critical updates correctly? - What is the Unique Device Identification (UDI) system and how might it solve this problem? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. Our services cover the entire product lifecycle, from initial regulatory strategy and technical dossier submission to post-market surveillance and continuous regulatory monitoring. By acting as your local representative in over 30 markets, we ensure your products not only get to market but also maintain compliance in complex, ever-changing regulatory landscapes. Visit us at https://pureglobal.com, contact info@pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.
    Show more Show less
    3 mins
  • Securing the MedTech Supply Chain: Blockchain vs. 3D-Printed Counterfeits

    Securing the MedTech Supply Chain: Blockchain vs. 3D-Printed Counterfeits
    Mar 14 2026
    The rise of sophisticated 3D-printed counterfeit medical devices presents a grave threat to patient safety and brand integrity. This episode delves into the escalating battle between counterfeiters and MedTech manufacturers, exploring the cutting-edge technologies being deployed to secure the global supply chain. We examine how solutions like blockchain and invisible marking technologies are becoming essential for verifying product authenticity, ensuring traceability, and complying with increasingly strict international regulations. Key Questions: - How has 3D printing revolutionized the counterfeit medical device industry? - What are the most significant risks counterfeit products pose to patients? - How does blockchain technology create a secure and traceable supply chain? - What are invisible markings, and how do they help verify a product's authenticity? - Why are these expensive technologies becoming a necessary investment for manufacturers? - How do anti-counterfeiting measures align with regulatory requirements like the FDA and EU UDI systems? - What is the impact of counterfeiting on a MedTech company's brand and market access? Navigating the complexities of global supply chain security and regulatory compliance is a significant challenge. Pure Global offers end-to-end consulting for MedTech and IVD companies, leveraging local expertise and advanced AI to streamline global market access. From developing regulatory strategies and managing technical submissions to ensuring post-market surveillance, Pure Global acts as your local representative in over 30 markets. Our technology-driven approach ensures efficiency and accuracy in securing your product's journey to market. Visit https://pureglobal.com/, contact us at info@pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your expansion.
    Show more Show less
    3 mins